those who want the deep scientific story

References on Hsp90

Foley et al., "Hsp90 inhibitor STA-9090 induces HIF-1? degradation in the hypoxic regions of solid tumors," AACR April 2010

Abstr 2638

Jhaveri et al., "Hsp90 Inhibitors for Cancer Therapy and Overcoming Drug Resistance," Advances in Pharmacology 65:471-

517 (2012)

Mahaseth et al., “Antiangiogenic Effects Associated with the Inhibition of HSP90 in Colorectal Cancer,” AACR 2012 Abstr

2326

Modi, S. et al., “HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in

patients with HER2-positive metastatic breast cancer progressing on trastuzumab,” Clin Cancer Res. 17:5132 (2011)

Neckers and Workman, “Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?” Clin Canc Res 18:64-76 (2012)

Taipale et al., "Quantitative Analysis of Hsp90-Client Interactions Reveals Principles of Substrate Recognition," Cell

150:987-1001 (2012)

Trepel et al., “Targeting the dynamic HSP90 complex in cancer,” Nat Rev Cancer 10:537-49 (2010)

Yamaki H et al., “Molecular basis for the actions of Hsp90 inhibitors and cancer therapy,” J Antibiotics 64: 635 (2011)

Ying et al., “Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior

safety profile for cancer therapy,” Molec Canc Therap 11:475 (2012)

Zhou et al., “Associating retinal drug exposure and retention with the ocular toxicity profiles of Hsp90 inhibitors,”  ASCO

June 2012 Abstr 3086